These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37349339)

  • 21. α-granule biogenesis: from disease to discovery.
    Chen CH; Lo RW; Urban D; Pluthero FG; Kahr WH
    Platelets; 2017 Mar; 28(2):147-154. PubMed ID: 28277061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    Albers CA; Cvejic A; Favier R; Bouwmans EE; Alessi MC; Bertone P; Jordan G; Kettleborough RN; Kiddle G; Kostadima M; Read RJ; Sipos B; Sivapalaratnam S; Smethurst PA; Stephens J; Voss K; Nurden A; Rendon A; Nurden P; Ouwehand WH
    Nat Genet; 2011 Jul; 43(8):735-7. PubMed ID: 21765411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Nbeal2(-/-) mouse as a model for the gray platelet syndrome.
    Deppermann C; Nurden P; Nurden AT; Nieswandt B; Stegner D
    Rare Dis; 2013; 1():e26561. PubMed ID: 25003009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet α-granules modulate the inflammatory response under systemic lipopolysaccharide injection in mice.
    Tariket S; Guerrero JA; Garraud O; Ghevaert C; Cognasse F
    Transfusion; 2019 Jan; 59(1):32-38. PubMed ID: 30394544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency.
    Catak MC; Akcam B; Bilgic Eltan S; Babayeva R; Karakus IS; Akgun G; Baser D; Bulutoglu A; Bayram F; Kasap N; Kiykim A; Hancioglu G; Kokcu Karadag SI; Kendir Demirkol Y; Ozen S; Cekic S; Ozcan D; Edeer Karaca N; Sasihuseyinoglu AS; Cansever M; Ozek Yucel E; Tamay Z; Altintas DU; Aydogmus C; Celmeli F; Cokugras H; Gulez N; Genel F; Metin A; Guner SN; Kutukculer N; Keles S; Reisli I; Kilic SS; Yildiran A; Karakoc-Aydiner E; Lo B; Ozen A; Baris S
    Allergy; 2022 Oct; 77(10):3108-3123. PubMed ID: 35491430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological phenotype of the murine Lrba knockout.
    Gámez-Díaz L; Neumann J; Jäger F; Proietti M; Felber F; Soulas-Sprauel P; Perruzza L; Grassi F; Kögl T; Aichele P; Kilimann M; Grimbacher B; Jung S
    Immunol Cell Biol; 2017 Oct; 95(9):789-802. PubMed ID: 28652580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of CTLA-4 recycling by LRBA and Rab11.
    Janman D; Hinze C; Kennedy A; Halliday N; Waters E; Williams C; Rowshanravan B; Hou TZ; Minogue S; Qureshi OS; Sansom DM
    Immunology; 2021 Sep; 164(1):106-119. PubMed ID: 33960403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons from CTLA-4 deficiency and checkpoint inhibition.
    Lo B; Abdel-Motal UM
    Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    Sims MC; Mayer L; Collins JH; Bariana TK; Megy K; Lavenu-Bombled C; Seyres D; Kollipara L; Burden FS; Greene D; Lee D; Rodriguez-Romera A; Alessi MC; Astle WJ; Bahou WF; Bury L; Chalmers E; Da Silva R; De Candia E; Deevi SVV; Farrow S; Gomez K; Grassi L; Greinacher A; Gresele P; Hart D; Hurtaud MF; Kelly AM; Kerr R; Le Quellec S; Leblanc T; Leinøe EB; Mapeta R; McKinney H; Michelson AD; Morais S; Nugent D; Papadia S; Park SJ; Pasi J; Podda GM; Poon MC; Reed R; Sekhar M; Shalev H; Sivapalaratnam S; Steinberg-Shemer O; Stephens JC; Tait RC; Turro E; Wu JKM; Zieger B; ; Kuijpers TW; Whetton AD; Sickmann A; Freson K; Downes K; Erber WN; Frontini M; Nurden P; Ouwehand WH; Favier R; Guerrero JA
    Blood; 2020 Oct; 136(17):1956-1967. PubMed ID: 32693407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Phenotypes and Immunological Characteristics of 18 Egyptian LRBA Deficiency Patients.
    Meshaal S; El Hawary R; Adel R; Abd Elaziz D; Erfan A; Lotfy S; Hafez M; Hassan M; Johnson M; Rojas-Restrepo J; Gamez-Diaz L; Grimbacher B; Shoman W; Abdelmeguid Y; Boutros J; Galal N; El-Guindy N; Elmarsafy A
    J Clin Immunol; 2020 Aug; 40(6):820-832. PubMed ID: 32506362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in Neurobeachin-like 2 do not impact Weibel-Palade body biogenesis and von Willebrand factor secretion in gray platelet syndrome Endothelial Colony Forming Cells.
    Kat M; van Moort I; Bürgisser PE; Kuijpers TW; Hofman M; Favier M; Favier R; Margadant C; Voorberg J; Bierings R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100086. PubMed ID: 36923710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gray platelet syndrome: NBEAL2 mutations are associated with pathology beyond megakaryocyte and platelet function defects.
    Pluthero FG; Kahr WHA
    J Thromb Haemost; 2021 Feb; 19(2):318-322. PubMed ID: 33300270
    [No Abstract]   [Full Text] [Related]  

  • 33. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice.
    Deppermann C; Cherpokova D; Nurden P; Schulz JN; Thielmann I; Kraft P; Vögtle T; Kleinschnitz C; Dütting S; Krohne G; Eming SA; Nurden AT; Eckes B; Stoll G; Stegner D; Nieswandt B
    J Clin Invest; 2013 Jul; 123(8):3331-42. PubMed ID: 23863626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency.
    Krone KA; Winant AJ; Vargas SO; Platt CD; Bartnikas LM; Janssen E; Lillehei C; Lee EY; Fishman MP; Casey A
    Pediatr Pulmonol; 2021 Jul; 56(7):2232-2241. PubMed ID: 33710794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective Zn
    Kiran Gotru S; van Geffen JP; Nagy M; Mammadova-Bach E; Eilenberger J; Volz J; Manukjan G; Schulze H; Wagner L; Eber S; Schambeck C; Deppermann C; Brouns S; Nurden P; Greinacher A; Sachs U; Nieswandt B; Hermanns HM; Heemskerk JWM; Braun A
    Sci Rep; 2019 Jun; 9(1):8333. PubMed ID: 31171812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Neurobeachin-like 2 protein (NBEAL2) controls the homeostatic level of the ribosomal protein RPS6 in mast cells.
    Wegner P; Drube J; Ziegler L; Strotmann B; Marquardt R; Küchler C; Groth M; Nieswandt B; Andreas N; Drube S
    Immunology; 2024 May; 172(1):61-76. PubMed ID: 38272677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
    Hou TZ; Verma N; Wanders J; Kennedy A; Soskic B; Janman D; Halliday N; Rowshanravan B; Worth A; Qasim W; Baxendale H; Stauss H; Seneviratne S; Neth O; Olbrich P; Hambleton S; Arkwright PD; Burns SO; Walker LS; Sansom DM
    Blood; 2017 Mar; 129(11):1458-1468. PubMed ID: 28159733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
    Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
    Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
    Gámez-Díaz L; Grimbacher B
    Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Expression of LRBA and CTLA-4 Proteins in Common Variable Immunodeficiency Patients.
    Salami F; Fekrvand S; Yazdani R; Shahkarami S; Azizi G; Bagheri Y; Delavari S; Shariati S; Mahdaviani SA; Nabavi M; Shirkani A; Abolhassani H; Samadi M; Aghamohammadi A
    Immunol Invest; 2022 Feb; 51(2):381-394. PubMed ID: 33191838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.